Florida Medicaid Asks Rx Manufacturer to Suspend “Broad Brush” 340B Pricing Restrictions, Will Other States Follow?
Florida’s Medicaid director has asked drug manufacturer Eli Lilly and Co. and reportedly other manufacturers to suspend its restrictions on 340B pricing on its products shipped to covered entities’ contract pharmacies, saying Lilly’s actions “threaten to negatively impact the health of Florida residents.”
Beth Kidder, Deputy Secretary for Medicaid in Florida’s Agency for Health Care Administration, made the request in a Nov. 23 letter to Lilly CEO David Ricks. Lilly is one of several drug manufacturers that are denying or imposing conditions on 340B pricing on products dispensed by contract pharmacies. AstraZeneca, Sanofi, Novartis, United Therapeutics, and Novo Nordisk are the others. 340B Report has been told that Kidder sent similar letters to some or all of those companies and we are working to confirm this.
.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
